173 related articles for article (PubMed ID: 1362164)
21. Immunohistochemical c-erbB-2 protooncogene expression and nuclear DNA content in human mammary carcinoma in situ.
Schimmelpenning H; Eriksson ET; Pallis L; Skoog L; Cedermark B; Auer GU
Am J Clin Pathol; 1992 May; 97(5 Suppl 1):S48-52. PubMed ID: 1374218
[TBL] [Abstract][Full Text] [Related]
22. Expression of c-erbB-2 protein in normal and neoplastic urothelium: lack of adverse prognostic effect in human urinary bladder cancer.
Lee SE; Chow NH; Chi YC; Tzai TS; Yang WH; Lin SN
Anticancer Res; 1994; 14(3B):1317-24. PubMed ID: 7915094
[TBL] [Abstract][Full Text] [Related]
23. LEA.135 expression: its comparison with other prognostic biomarkers for patients with primary breast carcinoma.
Liu D; Baltayan A; Naritoku WY; Barr NJ; Young LL; Chaiwun B; Tsao-Wei DD; Groshen SL; Taylor CR; Torloni H; Neville AM; Cote RJ; Imam SA
Anticancer Res; 2000; 20(3A):1451-61. PubMed ID: 10928056
[TBL] [Abstract][Full Text] [Related]
24. C-erbB-2 and PCNA as prognostic indicators of long-term survival in breast cancer.
Kato T; Kameoka S; Kimura T; Nishikawa T; Kobayashi M
Anticancer Res; 2002; 22(2B):1097-103. PubMed ID: 12168907
[TBL] [Abstract][Full Text] [Related]
25. Int-2/FGF3 amplification is a better independent predictor of relapse than c-myc and c-erbB-2/neu amplifications in primary human breast cancer.
Champème MH; Bièche I; Hacène K; Lidereau R
Mod Pathol; 1994 Dec; 7(9):900-5. PubMed ID: 7892157
[TBL] [Abstract][Full Text] [Related]
26. Expression of c-erbB-2 gene in human head and neck carcinoma.
Craven JM; Pavelic ZP; Stambrook PJ; Pavelic L; Gapany M; Kelley DJ; Gapany S; Gluckman JL
Anticancer Res; 1992; 12(6B):2273-6. PubMed ID: 1363518
[TBL] [Abstract][Full Text] [Related]
27. Multivariate analysis of bcl-2, apoptosis, P53 and HER-2/neu in breast cancer: a short-term follow-up.
el-Ahmady O; el-Salahy E; Mahmoud M; Wahab MA; Eissa S; Khalifa A
Anticancer Res; 2002; 22(4):2493-9. PubMed ID: 12174951
[TBL] [Abstract][Full Text] [Related]
28. The prognostic significance of epidermal growth factor receptor (EGFR), C-erbB-2, Ki-67 and PCNA expression in breast cancer.
Ioachim E; Kamina S; Athanassiadou S; Agnantis NJ
Anticancer Res; 1996; 16(5B):3141-7. PubMed ID: 8920782
[TBL] [Abstract][Full Text] [Related]
29. [Preliminary studies on c-erbB-2 protooncogene in breast cancer].
He LW
Zhonghua Zhong Liu Za Zhi; 1992 May; 14(3):171-4. PubMed ID: 1356719
[TBL] [Abstract][Full Text] [Related]
30. Human breast cancer: prognostic significance of the c-erbB-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features.
Gasparini G; Gullick WJ; Bevilacqua P; Sainsbury JR; Meli S; Boracchi P; Testolin A; La Malfa G; Pozza F
J Clin Oncol; 1992 May; 10(5):686-95. PubMed ID: 1349034
[TBL] [Abstract][Full Text] [Related]
31. Clinical and pathologic significance of the c-erbB-2 (HER-2/neu) oncogene.
Singleton TP; Strickler JG
Pathol Annu; 1992; 27 Pt 1():165-90. PubMed ID: 1346551
[TBL] [Abstract][Full Text] [Related]
32. c-erbB-4 protein expression in human breast cancer.
Kew TY; Bell JA; Pinder SE; Denley H; Srinivasan R; Gullick WJ; Nicholson RI; Blamey RW; Ellis IO
Br J Cancer; 2000 Mar; 82(6):1163-70. PubMed ID: 10735500
[TBL] [Abstract][Full Text] [Related]
33. [Current molecular prognostic factors in breast carcinoma].
Fey MF; Andres AC; Castiglione-Gertsch M
Schweiz Med Wochenschr; 1992 Oct; 122(40):1471-8. PubMed ID: 1357743
[TBL] [Abstract][Full Text] [Related]
34. Cathepsin D expression detected by immunohistochemistry has independent prognostic value in axillary node-negative breast cancer.
Isola J; Weitz S; Visakorpi T; Holli K; Shea R; Khabbaz N; Kallioniemi OP
J Clin Oncol; 1993 Jan; 11(1):36-43. PubMed ID: 8093367
[TBL] [Abstract][Full Text] [Related]
35. [Breast carcinoma in pregnancy. Clinical, histological and immunohistochemical findings].
Meden H; Marx D; Rath W; Tsikuras P; Kuhn W; Schauer A
Zentralbl Chir; 1992; 117(4):216-9. PubMed ID: 1351330
[TBL] [Abstract][Full Text] [Related]
36. Expression of the c-erbB-2 proto-oncogene product and nuclear DNA content in benign and malignant human breast parenchyma.
Schimmelpenning H; Eriksson ET; Falkmer UG; Azavedo E; Svane G; Auer GU
Virchows Arch A Pathol Anat Histopathol; 1992; 420(5):433-40. PubMed ID: 1350695
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of the combined assessment of proliferating cell nuclear antigen immunostaining and nuclear DNA content in invasive human mammary carcinomas.
Schimmelpenning H; Eriksson ET; Franzén B; Zetterberg A; Auer GU
Virchows Arch A Pathol Anat Histopathol; 1993; 423(4):273-9. PubMed ID: 7901939
[TBL] [Abstract][Full Text] [Related]
38. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer.
Paik S; Hazan R; Fisher ER; Sass RE; Fisher B; Redmond C; Schlessinger J; Lippman ME; King CR
J Clin Oncol; 1990 Jan; 8(1):103-12. PubMed ID: 1967301
[TBL] [Abstract][Full Text] [Related]
39. [Evaluation of immunoreactivity to erbB-2 protein as a marker of prognosis in bile duct carcinoma].
Motojima K; Komuta K; Hiasa A; Tsuribune T; Hashimoto T; Tsunoda T; Kanematsu T
Nihon Geka Gakkai Zasshi; 1992 Sep; 93(9):952-5. PubMed ID: 1361658
[TBL] [Abstract][Full Text] [Related]
40. The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer.
O'Reilly SM; Barnes DM; Camplejohn RS; Bartkova J; Gregory WM; Richards MA
Br J Cancer; 1991 Mar; 63(3):444-6. PubMed ID: 1672255
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
